Linked Life Data

12800191

Source:http://linkedlifedata.com/resource/pubmed/id/12800191

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2003-6-11
pubmed:abstractText
The roles of the cadherins in the progression of ovarian cancer to the late stages of the disease state when malignant cells have disseminated within the peritoneal cavity remain poorly understood. In view of these observations, we have undertaken a comprehensive survey of the cadherin subtypes present in normal ovarian surface epithelium and peritoneum and in the tumors and peritoneal effusions of women diagnosed with Stage I or Stage II primary ovarian cancer using a degenerate cloning strategy for sequences highly conserved among this family of cell adhesion molecules. On the basis of the nucleotide sequences of the resultant PCR products, multiple cadherin subtypes (E-, N-, P-cadherin, and cadherin-4, -6, and -11) were found to be present in these normal and malignant tissues and cells. P-cadherin was determined to be the predominant cadherin subtype in normal peritoneum, peritoneal effusions and Stage II tumor masses. An increase in P-cadherin mRNA and protein expression levels in ovarian tumor masses with progression to later stages of the disease state was confirmed by Northern and Western blot analysis, respectively. In addition, we have determined that the cadherin-associated protein, known as beta-catenin, is expressed in normal peritoneum, ovarian tumors and malignant cell effusions obtained from women with Stage I or Stage II cancer. Immunoprecipitation studies demonstrated that P-cadherin was capable of interacting with beta-catenin in these normal and malignant tissues and cells. Collectively, these findings suggest that the regulated expression of P-cadherin/beta-catenin complexes in ovarian tumor cells may represent a key step in disease progression.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0020-7136
pubmed:author
pubmed:copyrightInfo
Copyright 2003 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:day
20
pubmed:volume
106
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
172-7
pubmed:dateRevised
2007-7-24
pubmed:meshHeading
pubmed-meshheading:12800191-Ascitic Fluid, pubmed-meshheading:12800191-Blotting, Northern, pubmed-meshheading:12800191-Blotting, Western, pubmed-meshheading:12800191-Cadherins, pubmed-meshheading:12800191-Cytoskeletal Proteins, pubmed-meshheading:12800191-DNA Primers, pubmed-meshheading:12800191-Disease Progression, pubmed-meshheading:12800191-Female, pubmed-meshheading:12800191-Gene Expression Regulation, Neoplastic, pubmed-meshheading:12800191-Humans, pubmed-meshheading:12800191-Neoplasm Staging, pubmed-meshheading:12800191-Ovarian Neoplasms, pubmed-meshheading:12800191-Peritoneum, pubmed-meshheading:12800191-Pleural Effusion, Malignant, pubmed-meshheading:12800191-Polymerase Chain Reaction, pubmed-meshheading:12800191-Precipitin Tests, pubmed-meshheading:12800191-RNA, Messenger, pubmed-meshheading:12800191-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:12800191-Trans-Activators, pubmed-meshheading:12800191-beta Catenin
pubmed:year
2003
pubmed:articleTitle
Cadherin switching in ovarian cancer progression.
pubmed:affiliation
Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, British Columbia, Canada.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't